Publication at Second Faculty of Medicine |
2014
Abstract
Hyperglycaemia is an independent risk factor for cardiovascular morbidity and mortality. The best possible control of diabetes should therefore lead to a reduction in the incidence of cardiovascular events.
To obtain approval for the new drugs it is necessary to supply clinical trial data, including information about the effect of the drug on cardiovascular risk. For gliptins that have been marketed rather recently, some studies have already been conducted that can be said to have demonstrated the safety of these drugs.
However, it will still take time before we have study results that would fully satisfy the new FDA guidelines.